News
ADTX
0.0129
+1.57%
0.0002
Bank of America reports $0.15 disposal of 15 ADiTx common shares
PUBT · 6h ago
Aditxt initial beneficial ownership filing shows Bank of America as 10% owner
PUBT · 13h ago
Weekly Report: what happened at ADTX last week (0608-0612)?
Weekly Report · 20h ago
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 21h ago
Major Stakeholder Makes Bold Exit Move in Aditxt Stock
TipRanks · 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
HRT Financial disposes of 2,833,463 Aditxt common shares worth $39,668.48
PUBT · 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 3d ago
Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why
Benzinga · 3d ago
Major Investor Quietly Ramps Up Aditxt Stake With Bold Trading Move
TipRanks · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
HRT Financial LP sells 878,659 Aditxt shares worth $28,995
PUBT · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 4d ago
Copley Acquisition To Merge With Ignite Proteomics At Pro Forma EV Of $150M
Benzinga · 4d ago
Aditxt 10% owner Sandie Gong sells 100,000 shares for $6,880
PUBT · 5d ago
Aditxt Moves to Spin Off Ignite via SPAC Deal
TipRanks · 5d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 5d ago
More
Webull provides a variety of real-time ADTX stock news. You can receive the latest news about Aditxt Inc through multiple platforms. This information may help you make smarter investment decisions.
About ADTX
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.